Ontario’s bold reforms to drive down prices may not have any impact for employer benefit plans
In 2010, we saw the beginning of some aggressive measures that may very well transform the Canadian generic drug market from one that has been largely unregulated to one with strict government controls, not only of drug prices but the way business is conducted between drug manufacturers and pharmacies.
